We have located links that may give you full text access.
Journal Article
Review
Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.
European Urology Focus 2016 December
CONTEXT: After initiation of androgen deprivation therapy (ADT), most patients progress to castration-resistant prostate cancer (CRPC) within 2 or 3 yr. In the USA, approximately 67000 men are estimated to have metastatic CRPC.
OBJECTIVE: To provide an overview of different mechanisms driving resistance to therapy in metastatic CRPC, with a focus on androgen receptor (AR)-dependent pathways.
EVIDENCE ACQUISITION: A Medline search via PubMed was performed using the keywords metastatic castration resistant prostate cancer (mCRPC), castration-resistant, CRPC, prostate cancer, androgen resistance, hormone-refractory, hormone-independent, androgen receptor, and androgen receptor axis. Only articles in the English language were included. Abstracts and full-text articles were reviewed and assessed for relevant content. The majority of the articles selected were published between 1993 and 2016. Older studies were included selectively if relevant.
EVIDENCE SYNTHESIS: Numerous resistance mechanisms characterize the development of CRPC. The review focuses on AR-dependent pathways, including mechanisms of resistance to new agents. These include reactivation of AR (via AR amplification, mutations, or splice variants), stress-activated pathways, and aberrant activation of AR.
CONCLUSIONS: Mechanisms of resistance in CRPC are manifold and require multiple combinations of therapeutic approaches to be overcome. An understanding of the mechanisms by which resistance to ADT develops is the basis for identifying future therapeutic targets.
PATIENT SUMMARY: Castration-resistant prostate cancer is characterized by multiple resistance mechanisms to androgen deprivation treatment and remains an incurable disease. An understanding of the mechanisms underlying this resistance is necessary to identify future therapeutic targets.
OBJECTIVE: To provide an overview of different mechanisms driving resistance to therapy in metastatic CRPC, with a focus on androgen receptor (AR)-dependent pathways.
EVIDENCE ACQUISITION: A Medline search via PubMed was performed using the keywords metastatic castration resistant prostate cancer (mCRPC), castration-resistant, CRPC, prostate cancer, androgen resistance, hormone-refractory, hormone-independent, androgen receptor, and androgen receptor axis. Only articles in the English language were included. Abstracts and full-text articles were reviewed and assessed for relevant content. The majority of the articles selected were published between 1993 and 2016. Older studies were included selectively if relevant.
EVIDENCE SYNTHESIS: Numerous resistance mechanisms characterize the development of CRPC. The review focuses on AR-dependent pathways, including mechanisms of resistance to new agents. These include reactivation of AR (via AR amplification, mutations, or splice variants), stress-activated pathways, and aberrant activation of AR.
CONCLUSIONS: Mechanisms of resistance in CRPC are manifold and require multiple combinations of therapeutic approaches to be overcome. An understanding of the mechanisms by which resistance to ADT develops is the basis for identifying future therapeutic targets.
PATIENT SUMMARY: Castration-resistant prostate cancer is characterized by multiple resistance mechanisms to androgen deprivation treatment and remains an incurable disease. An understanding of the mechanisms underlying this resistance is necessary to identify future therapeutic targets.
Full text links
Related Resources
Trending Papers
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease.Pharmaceuticals 2024 March 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app